About: The interaction between the endocannabinoid system and the renin angiotensin system and its potential implication for COVID-19 infection

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The interaction between the endocannabinoid system and the renin angiotensin system and its potential implication for COVID-19 infection Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The interaction between the endocannabinoid system and the renin angiotensin system and its potential implication for COVID-19 infection
Creator	Heeroma, Joost Sainz-Cort, Alberto
Source	Medline; PMC
abstract	BACKGROUND: Coronavirus disease 2019 (COVID-19) is spreading fast all around the world with more than fourteen millions of detected infected cases and more than 600.000 deaths by 20th July 2020. While scientist are working to find a vaccine, current epidemiological data shows that the most common comorbidities for patients with the worst prognosis, hypertension and diabetes, are often treated with angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs). BODY: Both ACE inhibitors and ARBs induce overexpression of the angiotensin converting enzyme 2 (ACE-2) receptor, which has been identified as the main receptor used by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to enter into the alveolar cells of the lungs. While cannabinoids are known to reduce hypertension, the studies testing the hypotensive effects of cannabinoids never addressed their effects on ACE-2 receptors. However, some studies have linked the endocannabinoid system (ECS) with the renin angiotensin system (RAS), including a cross-modulation between the cannabinoid receptor 1 (CB1) and angiotensin II levels. CONCLUSION: Since there are around 192 million people using cannabis worldwide, we believe that the mechanism underlying the hypotensive properties of cannabinoids should be urgently studied to understand if they can also lead to ACE-2 overexpression as other antihypertensive drugs do.
has issue date	2020-07-31(xsd:dateTime)
bibo:doi	10.1186/s42238-020-00030-4
bibo:pmid	32835160
has license	cc-by
sha1sum (hex)	d2dceac725a0d30ae8069899c497567fb6e52dc6
schema:url	https://doi.org/10.1186/s42238-020-00030-4
resource representing a document's title	The interaction between the endocannabinoid system and the renin angiotensin system and its potential implication for COVID-19 infection
has PubMed Central identifier	PMC7393810
has PubMed identifier	32835160
schema:publication	J Cannabis Res
resource representing a document's body	covid:d2dceac725a0d30ae8069899c497567fb6e52dc6#body_text
is schema:about of	named entity 'cells' named entity 'epidemiological' named entity 'alveolar' named entity 'ACE' named entity 'studied' named entity 'hypotensive' named entity 'While' named entity 'ARBs' named entity 'endocannabinoid system' named entity 'OVEREXPRESSION' named entity 'ACE inhibitors' named entity 'reduce' named entity 'studies' named entity 'lead' named entity 'hypertension' named entity 'diabetes' named entity 'angiotensin' named entity 'converting' named entity 'ACE' named entity 'drugs' named entity 'prognosis' named entity 'effects' named entity 'Coronavirus disease 2019' named entity 'system' named entity 'angiotensin converting enzyme 2' named entity 'angiotensin' named entity 'renin' named entity 'ARBs' named entity 'vaccine' named entity 'hypertension' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'receptor' named entity 'ACE-2' named entity 'receptor' named entity 'antihypertensive drugs' named entity 'cannabinoids' named entity 'lungs' named entity 'ACE-2' named entity 'RAS' named entity 'renin' named entity 'angiotensin' named entity 'ARBs' named entity 'ACE' named entity 'World Drug Report' named entity 'hypotensive' named entity 'receptor' named entity 'cannabinoids' named entity 'Angiotensin converting enzyme' named entity 'hypertension' named entity 'malignancy' named entity 'cannabis' named entity 'scientific evidence' named entity 'angiotensin' named entity 'hypertension' named entity 'hypertensive' named entity 'human body' named entity 'ACE inhibitors' named entity 'RAS' named entity 'ACE inhibition' named entity 'cannabinoid receptor 1' named entity 'ACE-2' named entity 'prognosis' named entity 'COVID' named entity 'hypotensive' named entity 'chronic obstructive pulmonary disease' named entity 'angiotensin II' named entity 'CB1' named entity 'Angiotensin converting enzyme 2' named entity 'COVID-19' named entity 'cannabinoids' named entity 'prognosis' named entity 'angiotensin' named entity 'RAS' named entity 'antihypertensive drugs' named entity 'retrospective cohort study' named entity 'COVID-19 infection' named entity 'cannabinoids' named entity 'AT1R' named entity 'hypertension' named entity 'CB1'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software